NAV

Tranilast

Identification

Generic Name
Tranilast
DrugBank Accession Number
DB07615
Background

Tranilast is an antiallergic drug developed by Kissei Pharmaceuticals. In 1982, it was approved in Japan and South Korea for the management of bronchial asthma. Indications for keloid and hypertrophic scar were added in 1993. It has been used for the treatment of allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 327.3313
Monoisotopic: 327.110672659
Chemical Formula
C18H17NO5
Synonyms
  • N-(3,4-Dimethoxycinnamoyl)anthranilic acid
  • Tranilast
  • Tranilastum
External IDs
  • MK 341
  • MK-341
  • MK341
Poor quality drug data slowing you down?
Unlock 38% more drug discovery time and eliminate decision-making doubts with this one-stop guide to quality drug data.
Download eBook
Poor quality drug data slowing you down?
Download eBook

Pharmacology

Indication

For the treatment of bronchial asthma, keloid and hypertrophic scar, and allergic disorders such as asthma, allergic rhinitis and atopic dermatitis.

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UHematopoietic prostaglandin D synthase
inhibitor
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
Not Available

Interactions

Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AbametapirThe serum concentration of Tranilast can be increased when it is combined with Abametapir.
AbataceptThe metabolism of Tranilast can be increased when combined with Abatacept.
AbciximabThe risk or severity of bleeding can be increased when Tranilast is combined with Abciximab.
AbrocitinibThe risk or severity of bleeding and thrombocytopenia can be increased when Tranilast is combined with Abrocitinib.
AcarboseThe risk or severity of hypoglycemia can be increased when Tranilast is combined with Acarbose.
Food Interactions
Not Available

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Rizaben

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as n-cinnamoylanthranilic acids. These are aromatic compounds containing a cinnamic acid conjugated to an anthranilic acid.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Cinnamic acids and derivatives
Sub Class
Cinnamic acid amides
Direct Parent
N-cinnamoylanthranilic acids
Alternative Parents
Acylaminobenzoic acid and derivatives / Dimethoxybenzenes / Anilides / Benzoic acids / Styrenes / Phenoxy compounds / N-arylamides / Anisoles / Benzoyl derivatives / Alkyl aryl ethers
show 8 more
Substituents
Acylaminobenzoic acid or derivatives / Alkyl aryl ether / Anilide / Anisole / Aromatic homomonocyclic compound / Benzenoid / Benzoic acid / Benzoic acid or derivatives / Benzoyl / Carbonyl group
show 23 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
dimethoxybenzene, cinnamamides, amidobenzoic acid (CHEBI:77572)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
HVF50SMY6E
CAS number
53902-12-8
InChI Key
NZHGWWWHIYHZNX-CSKARUKUSA-N
InChI
InChI=1S/C18H17NO5/c1-23-15-9-7-12(11-16(15)24-2)8-10-17(20)19-14-6-4-3-5-13(14)18(21)22/h3-11H,1-2H3,(H,19,20)(H,21,22)/b10-8+
IUPAC Name
2-[(2E)-3-(3,4-dimethoxyphenyl)prop-2-enamido]benzoic acid
SMILES
COC1=CC=C(\C=C\C(=O)NC2=CC=CC=C2C(O)=O)C=C1OC

References

General References
Not Available
KEGG Drug
D02027
PubChem Compound
5282230
PubChem Substance
99444086
ChemSpider
4445411
BindingDB
21613
RxNav
57330
ChEBI
77572
ChEMBL
CHEMBL415324
ZINC
ZINC000000000797
PDBe Ligand
D27
Wikipedia
Tranilast
PDB Entries
2vd0

Clinical Trials

Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
PhaseStatusPurposeConditionsCount
4CompletedTreatmentAllergic Conjunctivitis (AC)1
4CompletedTreatmentHsCRP / NLRP3 / Percutaneous Coronary Intervention (PCI)1
3CompletedTreatmentPterygium1
2CompletedTreatmentActive Rheumatoid Arthritis; Rheumatoid Arthritis1
2CompletedTreatmentGout / Hyperuricemia2

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0084 mg/mLALOGPS
logP2.89ALOGPS
logP3.56Chemaxon
logS-4.6ALOGPS
pKa (Strongest Acidic)3.55Chemaxon
pKa (Strongest Basic)-2Chemaxon
Physiological Charge-1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area84.86 Å2Chemaxon
Rotatable Bond Count6Chemaxon
Refractivity91.52 m3·mol-1Chemaxon
Polarizability34.2 Å3Chemaxon
Number of Rings2Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.5905
Blood Brain Barrier-0.58
Caco-2 permeable+0.5
P-glycoprotein substrateNon-substrate0.6922
P-glycoprotein inhibitor INon-inhibitor0.7716
P-glycoprotein inhibitor IINon-inhibitor0.5842
Renal organic cation transporterNon-inhibitor0.9433
CYP450 2C9 substrateNon-substrate0.6853
CYP450 2D6 substrateNon-substrate0.8054
CYP450 3A4 substrateSubstrate0.5548
CYP450 1A2 substrateNon-inhibitor0.9137
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.9451
CYP450 2C19 inhibitorNon-inhibitor0.9167
CYP450 3A4 inhibitorNon-inhibitor0.8309
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7384
Ames testNon AMES toxic0.6665
CarcinogenicityNon-carcinogens0.871
BiodegradationNot ready biodegradable0.8218
Rat acute toxicity2.4428 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9921
hERG inhibition (predictor II)Non-inhibitor0.8008
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSsplash10-0006-1900000000-7541d25405a74d897cf6
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-1900000000-7541d25405a74d897cf6
MS/MS Spectrum - , positiveLC-MS/MSsplash10-0006-2900000000-d54b9ceefe589f6ddc0b
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-0006-0915000000-9a189969825e063aab0b
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-03dr-0694000000-4a4eb7e5dbd30d5dfaba
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-03dl-0914000000-35c7f84e713d8062c539
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0uxr-0590000000-7afea40c6f04a033e157
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-020r-2921000000-80d334909264542b236f
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-014i-0890000000-aaa94c536003cd5240c1
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-197.5819972
predicted
DarkChem Lite v0.1.0
[M-H]-171.17595
predicted
DeepCCS 1.0 (2019)
[M+H]+197.9771972
predicted
DarkChem Lite v0.1.0
[M+H]+173.57497
predicted
DeepCCS 1.0 (2019)
[M+Na]+181.74144
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Hematopoietic prostaglandin D synthase
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Protein homodimerization activity
Specific Function
Bifunctional enzyme which catalyzes both the conversion of PGH2 to PGD2, a prostaglandin involved in smooth muscle contraction/relaxation and a potent inhibitor of platelet aggregation, and the con...
Gene Name
HPGDS
Uniprot ID
O60760
Uniprot Name
Hematopoietic prostaglandin D synthase
Molecular Weight
23343.65 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]
  2. Ikai K, Ujihara M, Fujii K, Urade Y: Inhibitory effect of tranilast on prostaglandin D synthetase. Biochem Pharmacol. 1989 Aug 15;38(16):2673-6. [Article]

Enzymes

Details1. Cytochrome P450 3A4
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Uesawa Y, Takeuchi T, Mohri K: Integrated analysis on the physicochemical properties of dihydropyridine calcium channel blockers in grapefruit juice interactions. Curr Pharm Biotechnol. 2012 Jul;13(9):1705-17. [Article]
Details2. Cytochrome P450 2C9
Kind
Protein
Organism
Humans
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2C9
Uniprot ID
P11712
Uniprot Name
Cytochrome P450 2C9
Molecular Weight
55627.365 Da
References
  1. Katoh M, Matsui T, Yokoi T: Glucuronidation of antiallergic drug, Tranilast: identification of human UDP-glucuronosyltransferase isoforms and effect of its phase I metabolite. Drug Metab Dispos. 2007 Apr;35(4):583-9. doi: 10.1124/dmd.106.013706. Epub 2007 Jan 12. [Article]

Drug created at September 15, 2010 21:24 / Updated at January 14, 2023 19:03